Cargando…

CD70-Targeted Micelles Enhance HIF2α siRNA Delivery and Inhibit Oncogenic Functions in Patient-Derived Clear Cell Renal Carcinoma Cells

The majority of clear cell renal cell carcinomas (ccRCCs) are characterized by mutations in the Von Hippel–Lindau (VHL) tumor suppressor gene, which leads to the stabilization and accumulation of the HIF2α transcription factor that upregulates key oncogenic pathways that promote glucose metabolism,...

Descripción completa

Detalles Bibliográficos
Autores principales: Trac, Noah, Oh, Hyun Seok, Jones, Leila Izzy, Caliliw, Randy, Ohtake, Shinji, Shuch, Brian, Chung, Eun Ji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9738223/
https://www.ncbi.nlm.nih.gov/pubmed/36500549
http://dx.doi.org/10.3390/molecules27238457
_version_ 1784847485480468480
author Trac, Noah
Oh, Hyun Seok
Jones, Leila Izzy
Caliliw, Randy
Ohtake, Shinji
Shuch, Brian
Chung, Eun Ji
author_facet Trac, Noah
Oh, Hyun Seok
Jones, Leila Izzy
Caliliw, Randy
Ohtake, Shinji
Shuch, Brian
Chung, Eun Ji
author_sort Trac, Noah
collection PubMed
description The majority of clear cell renal cell carcinomas (ccRCCs) are characterized by mutations in the Von Hippel–Lindau (VHL) tumor suppressor gene, which leads to the stabilization and accumulation of the HIF2α transcription factor that upregulates key oncogenic pathways that promote glucose metabolism, cell cycle progression, angiogenesis, and cell migration. Although FDA-approved HIF2α inhibitors for treating VHL disease-related ccRCC are available, these therapies are associated with significant toxicities such as anemia and hypoxia. To improve ccRCC-specific drug delivery, peptide amphiphile micelles (PAMs) were synthesized incorporating peptides targeted to the CD70 marker expressed by ccRCs and anti-HIF2α siRNA, and the ability of HIF2α-CD27 PAMs to modulate HIF2α and its downstream targets was evaluated in human ccRCC patient-derived cells. Cell cultures were derived from eight human ccRCC tumors and the baseline mRNA expression of HIF2A and CD70, as well as the HIF2α target genes SLC2A1, CCND1, VEGFA, CXCR4, and CXCL12 were first determined. As expected, each gene was overexpressed by at least 63% of all samples compared to normal kidney proximal tubule cells. Upon incubation with HIF2α-CD27 PAMs, a 50% increase in ccRCC-binding was observed upon incorporation of a CD70-targeting peptide into the PAMs, and gel shift assays demonstrated the rapid release of siRNA (>80% in 1 h) under intracellular glutathione concentrations, which contributed to ~70% gene knockdown of HIF2α and its downstream genes. Further studies demonstrated that knockdown of the HIF2α target genes SLC2A1, CCND1, VEGFA, CXCR4, and CXCL12 led to inhibition of their oncogenic functions of glucose transport, cell proliferation, angiogenic factor release, and cell migration by 50–80%. Herein, the development of a nanotherapeutic strategy for ccRCC-specific siRNA delivery and its potential to interfere with key oncogenic pathways is presented.
format Online
Article
Text
id pubmed-9738223
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97382232022-12-11 CD70-Targeted Micelles Enhance HIF2α siRNA Delivery and Inhibit Oncogenic Functions in Patient-Derived Clear Cell Renal Carcinoma Cells Trac, Noah Oh, Hyun Seok Jones, Leila Izzy Caliliw, Randy Ohtake, Shinji Shuch, Brian Chung, Eun Ji Molecules Article The majority of clear cell renal cell carcinomas (ccRCCs) are characterized by mutations in the Von Hippel–Lindau (VHL) tumor suppressor gene, which leads to the stabilization and accumulation of the HIF2α transcription factor that upregulates key oncogenic pathways that promote glucose metabolism, cell cycle progression, angiogenesis, and cell migration. Although FDA-approved HIF2α inhibitors for treating VHL disease-related ccRCC are available, these therapies are associated with significant toxicities such as anemia and hypoxia. To improve ccRCC-specific drug delivery, peptide amphiphile micelles (PAMs) were synthesized incorporating peptides targeted to the CD70 marker expressed by ccRCs and anti-HIF2α siRNA, and the ability of HIF2α-CD27 PAMs to modulate HIF2α and its downstream targets was evaluated in human ccRCC patient-derived cells. Cell cultures were derived from eight human ccRCC tumors and the baseline mRNA expression of HIF2A and CD70, as well as the HIF2α target genes SLC2A1, CCND1, VEGFA, CXCR4, and CXCL12 were first determined. As expected, each gene was overexpressed by at least 63% of all samples compared to normal kidney proximal tubule cells. Upon incubation with HIF2α-CD27 PAMs, a 50% increase in ccRCC-binding was observed upon incorporation of a CD70-targeting peptide into the PAMs, and gel shift assays demonstrated the rapid release of siRNA (>80% in 1 h) under intracellular glutathione concentrations, which contributed to ~70% gene knockdown of HIF2α and its downstream genes. Further studies demonstrated that knockdown of the HIF2α target genes SLC2A1, CCND1, VEGFA, CXCR4, and CXCL12 led to inhibition of their oncogenic functions of glucose transport, cell proliferation, angiogenic factor release, and cell migration by 50–80%. Herein, the development of a nanotherapeutic strategy for ccRCC-specific siRNA delivery and its potential to interfere with key oncogenic pathways is presented. MDPI 2022-12-02 /pmc/articles/PMC9738223/ /pubmed/36500549 http://dx.doi.org/10.3390/molecules27238457 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Trac, Noah
Oh, Hyun Seok
Jones, Leila Izzy
Caliliw, Randy
Ohtake, Shinji
Shuch, Brian
Chung, Eun Ji
CD70-Targeted Micelles Enhance HIF2α siRNA Delivery and Inhibit Oncogenic Functions in Patient-Derived Clear Cell Renal Carcinoma Cells
title CD70-Targeted Micelles Enhance HIF2α siRNA Delivery and Inhibit Oncogenic Functions in Patient-Derived Clear Cell Renal Carcinoma Cells
title_full CD70-Targeted Micelles Enhance HIF2α siRNA Delivery and Inhibit Oncogenic Functions in Patient-Derived Clear Cell Renal Carcinoma Cells
title_fullStr CD70-Targeted Micelles Enhance HIF2α siRNA Delivery and Inhibit Oncogenic Functions in Patient-Derived Clear Cell Renal Carcinoma Cells
title_full_unstemmed CD70-Targeted Micelles Enhance HIF2α siRNA Delivery and Inhibit Oncogenic Functions in Patient-Derived Clear Cell Renal Carcinoma Cells
title_short CD70-Targeted Micelles Enhance HIF2α siRNA Delivery and Inhibit Oncogenic Functions in Patient-Derived Clear Cell Renal Carcinoma Cells
title_sort cd70-targeted micelles enhance hif2α sirna delivery and inhibit oncogenic functions in patient-derived clear cell renal carcinoma cells
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9738223/
https://www.ncbi.nlm.nih.gov/pubmed/36500549
http://dx.doi.org/10.3390/molecules27238457
work_keys_str_mv AT tracnoah cd70targetedmicellesenhancehif2asirnadeliveryandinhibitoncogenicfunctionsinpatientderivedclearcellrenalcarcinomacells
AT ohhyunseok cd70targetedmicellesenhancehif2asirnadeliveryandinhibitoncogenicfunctionsinpatientderivedclearcellrenalcarcinomacells
AT jonesleilaizzy cd70targetedmicellesenhancehif2asirnadeliveryandinhibitoncogenicfunctionsinpatientderivedclearcellrenalcarcinomacells
AT caliliwrandy cd70targetedmicellesenhancehif2asirnadeliveryandinhibitoncogenicfunctionsinpatientderivedclearcellrenalcarcinomacells
AT ohtakeshinji cd70targetedmicellesenhancehif2asirnadeliveryandinhibitoncogenicfunctionsinpatientderivedclearcellrenalcarcinomacells
AT shuchbrian cd70targetedmicellesenhancehif2asirnadeliveryandinhibitoncogenicfunctionsinpatientderivedclearcellrenalcarcinomacells
AT chungeunji cd70targetedmicellesenhancehif2asirnadeliveryandinhibitoncogenicfunctionsinpatientderivedclearcellrenalcarcinomacells